Kurs & Likviditet
Prenumeration
Du har en aktiv prenumeration.
Prenumerera på pressmeddelanden från Prostatype Genomics via email.
Du prenumererar på följande språk.
Välj vilka språk du vill prenumerera på.
Modular Finance AB kommer att hantera vissa av dina personuppgifter om du väljer att prenumerera. Mer information om vår personuppgiftshantering finns här.
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
2024-01-16 09:30:00
2024-01-16 09:30
Prostatype Genomics AB ("Prostatype Genomics" or the "Company") has completed a rights issue of units, consisting of shares and warrants of series 3, that closed on January 5, 2024. The rights issue is now registered with the Swedish Companies Registration Office and the last day of trading in paid subscription units (“BTU”) is January 17, 2024. The record date is January 19, 2024, after which BTUs are converted into shares and warrants of series 3 (“TO3”) on January 23, 2024. The new shares and TO3 warrants will be listed on Nasdaq First North Growth Market and the last day of trading in TO3 is April 17, 2024.
For further information about Prostatype Genomics, please contact:
Fredrik Persson, CEO
Telephone: +46 (0) 73 049 77 01.
e-mail: fredrik.persson@prostatypegenomics.com
Certified Adviser
Carnegie Investment Bank AB (publ), +46 (0)73 856 4265, certifiedadviser@carnegie.se
About Prostatype Genomics AB
Prostatype® is a genetic test that is available to patients and treating urologists as a supplementary decision support tool to answer the question of radical treatment or no radical treatment of prostate cancer. The test is developed by a research group at Karolinska Institutet and is provided by Prostatype Genomics AB.